Psoriasis is a chronic inflammatory skin disease characterized by epidermal hyperplasia (Acanthosis) with elongated ridges and abnormal differentiation of epidermal keratinocytes, dermal angiogenesis, abnormal accumulation of polymorphonuclear leukocytes, infiltration of activated T cells and dendritic cells, and increased cytokine levels. MatTek has developed in vitro model of Psoriasis to enable the study of the disease, and to screen therapeutic candidates for safety and efficacy.
MatTek’s diseased 3D model of psoriasis is produced from normal human epidermal keratinocytes and psoriatic fibroblasts harvested from psoriatic lesions. The cells are cultured on specially prepared cell culture inserts using serum free medium to form a multilayered, highly differentiated tissue. The Psoriasis tissues maintain a psoriatic phenotype as evidenced by increased basal cell proliferation, expression of psoriasis-specific markers and elevated release of psoriasis-specific cytokines. Morphologically, the tissue model closely parallels lesional psoriatic human tissues. This model provides researchers with a human relevant, highly controlled in vitro model to assess the safety and efficacy of lead therapeutic compounds and to study other basic psoriasis biology phenomena.
The psoriasis tissue model exhibits a psoriatic phenotype as evidenced by increased expression of psoriasis-associated markers including human β-defensin-2 (HBD2), psoriasin, SKALP/elafin, keratinocyte hyperproliferative cells and proinflammatory cytokines/ chemokines such as IL-6, IL-8, GM-CSF, and IP-10. Additionally, MatTek’s Psoriasis model can be produced from 6 different donors allowing for the study of therapeutics while accounting for biological variability between donors.
The in vitro Psoriasis model is responsive to marketed anti-psoriatic therapeutics and is amenable to model skin – immune system interactions with the exogenous addition of soluble immune cell factors.
Anti-Psoriasis Drug Screening
The model provides researchers with a useful, in vitro means to assess the pre-clinical safety and efficacy of lead therapeutic compounds.
Psoriasis Disease Research
The tissue model closely parallels lesional psoriatic human tissues in terms of morphology and cytokine expression. This model provides researchers with a useful, in vitro means to study psoriasis biology phenomena.
Search our library of technical papers for more information.
Kit: The Psoriasis Tissue Kit (SOR-300-FT) consists of 24 tissues.
Substrate: Millipore Millicell™ Cell culture insert used. Pore size = 0.4 μm, Diameter = 0.8 cm, Surface area = 0.6 cm2.
Culture: At air liquid interface (apical tissue surface exposed to the atmosphere).
Histology: 8-12 cell layers plus stratum corneum (basal, spinous, and granular layers).
Lot Numbers: Tissue lots are produced every other week and are assigned a specific lot number. A letter of the alphabet is appended to the end of the lot number to differentiate between individual kits within a given lot of tissues. All tissue kits within a lot are identical in regards to cells, medium, handling, culture conditions, etc.
Shipment: At 2-8°C on medium-supplemented, agarose gels in 24-well plates.
Shipment day: Every other Monday.
Delivery: Tuesday morning via FedEx priority service (US). Outside US: Tuesday-Thursday depending on location.
Shelf life: Including time in transit, tissues may be stored in their original package at 2-8°C for up to 4 days prior to use. The best reproducibility will be obtained if tissues are used consistently on the same day, e.g. Tuesday afternoon or following overnight storage at 2-8°C (Wednesday morning). Extended storage periods are not recommended.
Length of experiments: Cultures can be continued for up to 2 weeks with good retention of normal epidermal morphology. Cultures must be fed every other day with 5.0 ml of SOR-300-FT-MM medium. Culture stands (MatTek part #: MEL-STND) are required for experiments in excess of 24 hrs.
SOR-300-FT-ABF: Antibiotic-free tissue. For last 3 days of culture, gentamicin is omitted from culture medium. Customer also receives SOR-300-FT-MM-AFAB medium.
SOR-300-FT-AFF: Anti-fungal-free tissue. For last 3 days of culture, Amphotericin is omitted from culture medium. Customer also receives SOR-300-FT-MM-AFAB medium.
SOR-300-FT-AFAB: Antibiotic, anti-fungal-free tissue. For last 3 days of culture, gentamicin and Amphotericin are omitted from culture medium. Customer also receives SOR-300-FT-MM-AFAB medium.
SOR-300-FT-CTR: Normal healthy control tissue for psoriasis experiments
Type: Normal human epidermal keratinocytes (NHEK); psoriatic human dermal fibroblasts (PHDF).
Derived from: Neonatal-foreskin tissue (NHEK); adult psoriatic explants (PHDF)
Screened for: HIV, Hepatitis-B, Hepatitis-C, and mycoplasma.
Base medium: Dulbecco’s Modified Eagle’s Medium (DMEM).
Growth factors/hormones: Epidermal growth factor, insulin, hydrocortisone and other proprietary stimulators of epidermal differentiation.
Antibiotics: Gentamicin 5 µg/ml (10% of the normal gentamicin level).
Anti-fungal agent: Amphotericin B 0.25 µg/ml.
pH Indicator: Phenol red.
Other additives: Lipid precursors used to enhance epidermal barrier formation (proprietary).
Alternatives: Phenol red-free (SOR-300-FT-PRF), antibiotic-free (SOR-300-FT-ABF), anti-fungal-free (SOR-300-FT-AFF), or hydrocortisone-free medium and tissue (SOR-300-FT-HCF) are available. Agents are removed 3 days prior to shipment.
Assay/Maintenance medium: SOR-300-FT-MM is used for equilibration of tissues following shipment and for maintenance of the SOR-300-FT tissues in culture during experiments.
Quality Control and Sterility:
Visual inspection: All tissues are visually inspected and if physical imperfections are noted, tissues are rejected for shipment.
End-use testing: Tissues are exposed to 1% Triton X-100 for 4, 6, 8 and 10 hours. The time of exposure required to reduce the tissue viability (ET-50) using the MTT viability assay is determined (See MatTek Psoriasis Tissue use protocol) for each lot of tissue. ET-50’s generally fall within the range of 6.0-12.0 hours. ET-50’s in customers’ lab may differ slightly from the MatTek results. In addition, qPCR data for psoriasis related genes will be monitored. Increases of >5 fold for psoriasin, human beta-defensin-2 and elafin are expected.
Sterility: All media used throughout the production process is checked for sterility. Maintenance medium is incubated with and without antibiotics for 1 week and checked for sterility. The agarose gel from the 24-well plate used for shipping is also incubated for 1 week and checked for any sign of contamination.
Screening for pathogens: All cells are screened and are negative for HIV, hepatitis B and hepatitis C using PCR. However, no known test method can offer complete assurance that the cells are pathogen free. Thus, these products and all human derived products should be handled at BSL-2 levels (biosafety level 2) or higher as recommended in the CDC-NIH manual, “Biosafety in microbiological and biomedical laboratories,” 1998. For further assistance, please contact your site Safety Officer or MatTek technical service.
Notification of lot failure: If a tissue lot fails our QC or sterility testing, the customer will be notified and the tissues will be replaced without charge when appropriate. Because our QC and sterility testing is done post-shipment, notification will be made as soon as possible (Under normal circumstances, ET-50 failures will be notified by Thursday 5 pm; sterility failures will be notified within 8 days of shipment).
To ensure that the most appropriate products and accessories for your application are included with your initial order, MatTek strongly recommends a complimentary consultation with one of our highly trained Technical Specialists. Please contact Jonathan Oldach to order Psoriasis products.
T: (508) 881-6771 Ext. 210
F: (508) 879-1532
All Other Orders
Please contact Customer Service via telephone or fax.
T: (508) 881-6771
Cost-Effective & Reproducible
All MatTek tissue models are produced to the highest quality.
- UNSURPASSED LONG-TERM TISSUE REPRODUCIBILITY LOT-TO-LOT, YEAR-TO-YEAR
- 3-DIMENTIONAL, HIGHLY DIFFERENTIATED TISSUE
- METABOLICALLY, MITOTICALLY ACTIVE